Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioPharmX Corporation (OTC: BPMX).

Full DD Report for BPMX

You must become a subscriber to view this report.


Recent News from (OTC: BPMX)

BioPharmX Corporation beats on revenue
BioPharmX Corporation (NYSEMKT: BPMX ): Q2 GAAP EPS of -$0.02. More news on: BioPharmX Corporation, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 30 2018 16:22
BioPharmX Reports Second Quarter 2019 Financial Results
MENLO PARK, Calif. , Aug. 30, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial results for the quarter ended July 31, 2018 . "This quarter has been filled ...
Source: PR Newswire
Date: August, 30 2018 16:15
Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX - What Drives Growth in Today's Competitive Landscape
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allegheny Technologies Incorporated (NYSE:ATI), Ring Energy, Inc. (NYSE:R...
Source: GlobeNewswire
Date: August, 28 2018 07:55
BioPharmX Announces Results of Annual Shareholders Meeting
MENLO PARK, Calif. , Aug. 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today held its 2018 Annual Meeting of Shareholders (the "Annual Meeting"), and announced that each of Bio...
Source: PR Newswire
Date: August, 14 2018 18:00
BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms
MENLO PARK, Calif. , Aug. 9, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Patent and Trademark Office has granted a fifth patent to the company ȁ...
Source: PR Newswire
Date: August, 09 2018 06:15
BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea
MENLO PARK, Calif. , July 31, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced it has received Institutional Review Board approval for its phase 2 study of BPX-04 for t...
Source: PR Newswire
Date: July, 31 2018 09:15
Free Technical Insights on BioPharmX and Three Other Biotech Stocks
Stock Research Monitor: BMRN, CATB, and GBT LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration . WallStEquities.com shifts focus on the Biotechnology space, which consists of companies that are engaged in...
Source: ACCESSWIRE IA
Date: July, 26 2018 08:00
Today's Research Reports on Stocks to Watch: MiMedx Group and BiopharmX
NEW YORK, NY / ACCESSWIRE / July 20, 2018 / MiMedx Group and BioPharmX both saw big jumps after announcing positive news. The former announced the appointment of a new Chief Compliance Officer while the latter announced that the Food and Drug Administration has waived its requirement for a d...
Source: ACCESSWIRE IA
Date: July, 20 2018 08:05
3 Biotech Stocks to Watch This Quarter
CORAL GABLES, FL / ACCESSWIRE / July, 19 2018 / President Trump continues to put down the pharmaceutical industry on a regular basis, despite this biotech stocks are doing well over the last year. Since August 10 of 2017, the SPDR S&P Biotech ETF (XBI) has been firing on all cylinders. ...
Source: ACCESSWIRE IA
Date: July, 19 2018 11:17
BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01
MENLO PARK, Calif. , July 19, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Food and Drug Administration has waived its requirement for a dermal carcinogeni...
Source: PR Newswire
Date: July, 19 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.11720.11620.120.1151,945,469
2018-12-130.1250.11650.1250.116162,408,056
2018-12-120.1230.12140.12590.113,200,463
2018-12-110.13290.1240.13290.124,669,335
2018-12-100.1450.13020.1450.1293,550,198

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on BPMX.


About BioPharmX Corporation (OTC: BPMX)

Logo for BioPharmX Corporation (OTC: BPMX)

BioPharmX, Inc. provides innovative drug delivery products through its unique, patented platform technologies for pharmaceutical and OTC applications.

 

Contact Information

 

 

Current Management

  • James Pekarsky / CEO, CFO, Treasurer
  • Anja Krammer / President, Secretary
  • Stephen Morlock / Director, Business Control
  • Kin Foong Chan / Research amp Development
  • James Pekarsky / Chairman
  • Michael Hubbard /
  • Anja Krammer /

Current Share Structure

  • Market Cap: $3,746,409 - 03/20/2018
  • Authorized: 100,000,000 - 02/28/2018
  • Issue and Outstanding: 12,026,994 - 02/28/2018

 


Recent Filings from (OTC: BPMX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: December, 12 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017

 

 


Daily Technical Chart for (OTC: BPMX)

Daily Technical Chart for (OTC: BPMX)


Stay tuned for daily updates and more on (OTC: BPMX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BPMX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BPMX and does not buy, sell, or trade any shares of BPMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/